Published August 19, 2019
| Version v2
Journal article
Open
Optimisation of the delivery of ribonucleoprotein (RNP) complexes into SU-DIPG-IV cells by electroporation
- 1. Structural Genomics Consortium, University of Oxford
Description
A report/protocol for the optimisation of delivery of ribonucleoprotein (RNP) complexes into the patient derived DIPG cell line (SU-DIPG-IV) using electroporation. Electroporation was performed with the Neon electroporation system. RNPs consisting of sgRNA and AlexaFluor488 anti-mouse antibodies were used as a proxy for the Cas9/sgRNA RNPs to be delivered for CRISPR/Cas9 mediated genome editing.
Notes
Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
Files
2020.08.05 SU DIPG IV electroporation optimisation report_higher amplitude analysis.pdf
Files
(23.0 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:cc1765938eb2f2001e4c489994ccacf4
|
22.5 MB | Preview Download |
|
md5:bf4564a38087812b8ed9fc5389c6e0d0
|
540.5 kB | Preview Download |